15 Facts About Adalimumab

Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.

Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha.

Adalimumab was approved for medical use in the United States in 2002.

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults.

Adalimumab has been shown to reduce the signs and symptoms of, and is approved for treatment for, ankylosing spondylitis in adults.

Related searches

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe Crohn's disease.

Adalimumab has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis.

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children aged four years and older.

Adalimumab is indicated for the treatment of non-infectious uveitis.

Adalimumab was the first fully human monoclonal antibody approved by the US Food and Drug Administration.

Adalimumab was discovered as a result of a collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology, UK, itself a collaboration of the government-funded Medical Research Council and three academics, which began in 1993.

Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002.

Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.

Adalimumab biosimilars became available in the European Union in 2018, allowing the National Health Service to make record-breaking cost-savings, as this is the single most expensive drug used in NHS hospitals, costing more than £400million a year for about 46,000 patients.

In June 2020, a class action lawsuit filed by United Food and Commercial Workers Local 1500 against AbbVie, alleging that the drug manufacturer used a patent thicket over 100 strong to maintain a monopoly on Adalimumab, was dismissed by the Northern District Court in Illinois.